Flavopiridol induces apoptosis in glioma cell lines independent of retinoblastoma and p53 tumor suppressor pathway alterations by a caspase-independent pathway

Molecular Cancer Therapeutics

Volumn 2, Issue 2, 2003, Pages 139-150

  Alonso, Michelle ^a   Tamasdan, Cristina ^a   Miller, Douglas C ^a   Newcomb, Elizabeth W ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTOSIS INDUCING FACTOR; CASP8 PROTEIN, HUMAN; CASP8 PROTEIN, MOUSE; CASP9 PROTEIN, HUMAN; CASP9 PROTEIN, MOUSE; CASPASE; CASPASE 8; CASPASE 9; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE; CYTOCHROME C; ENZYME INHIBITOR; FLAVONOID; FLAVOPIRIDOL; FLAVOPROTEIN; MDM2 PROTEIN, HUMAN; MEMBRANE PROTEIN; NUCLEAR PROTEIN; ONCOPROTEIN; PDCD8 PROTEIN, HUMAN; PIPERIDINE DERIVATIVE; PROTEIN MDM2; PROTEIN P53; RETINOBLASTOMA PROTEIN;

APOPTOSIS; ARTICLE; BRAIN TUMOR; CELL CULTURE; CELL DIVISION; DRUG ANTAGONISM; DRUG EFFECT; ELECTRON MICROSCOPY; ENZYME IMMUNOASSAY; FLOW CYTOMETRY; GENETICS; GLIOMA; HUMAN; METABOLISM; NORTHERN BLOTTING; PATHOLOGY; PHYSIOLOGY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS INDUCING FACTOR; BLOTTING, NORTHERN; BRAIN NEOPLASMS; CASPASE 8; CASPASE 9; CASPASES; CELL CYCLE PROTEINS; CELL DIVISION; CYCLIN-DEPENDENT KINASES; CYTOCHROME C GROUP; ENZYME INHIBITORS; FLAVONOIDS; FLAVOPROTEINS; FLOW CYTOMETRY; GLIOMA; HUMANS; IMMUNOENZYME TECHNIQUES; MEMBRANE PROTEINS; MICROSCOPY, ELECTRON; NUCLEAR PROTEINS; PIPERIDINES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RETINOBLASTOMA PROTEIN; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0041488913     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Sherr, C. J. The INK4a/ARF network in tumour suppression. Nat. Rev., 2: 731-737, 2001. (Pubitemid 33679835)
2. Kleihues, P., Burger, P. C., Collins, P., Newcomb, E. W., Ohgaki, H., and Cavenee, W. K. Glioblastoma. In: P. Kleihues and W. K. Cavenee (eds.), Pathology and Genetics of Tumours of the Nervous System, pp. 29-39. Lyon, France: IARC Press, 2000.
3. Louis, D. N., Holland, E. C., and Cairncross, J. G. Glioma classification: a molecular reappraisal. Am. J. Pathol., 159: 779-786, 2001. (Pubitemid 32847166)
4. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell, 88: 323-331, 1997. (Pubitemid 27131374)
5. Balint, E., and Vousden, K. H. Activation and activities of the p53 tumour suppressor protein. Br. J. Cancer, 85: 1813-1823, 2001. (Pubitemid 34775315)
6. Lang, F. F., Miller, D. C., Koslow, M., and Newcomb, E. W. Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors. J. Neurosurg., 81: 427-436, 1994. (Pubitemid 24267651)
7. Newcomb, E. W., Cohen, H., Lee, S. R., Bhalla, S. K., Bloom, J., Hayes, R. L., and Miller, D. C. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2, or Bcl-2 genes. Brain Pathol., 8: 655-667, 1998. (Pubitemid 28460924)
8. Kondo, S., Barnett, G. H., Hara, H., Morimura, T., and Takeuchi, J. MDM2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis. Oncogene, 10: 2001-2006, 1995.
9. Chen, L., Agrawal, S., Zhou, W., Zhang, R., and Chen, J. Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. Proc. Natl. Acad. Sci. USA, 95: 195-200, 1998. (Pubitemid 28103930)
10. Johnstone, R. W., Ruefli, A. A., and Lowe, S. W. Apoptosis: A link between cancer genetics and chemotherapy. Cell, 108: 153-164, 2002. (Pubitemid 34161136)
11. Sherr, C. J., and Weber, J. D. The ARF/p53 pathway. Curr. Opin. Genet. Dev., 10: 94-99, 2000. (Pubitemid 30113711)
12. Naik, R. G., Kattige, S. L., Bhat, S. B., Alreja, B., De Souza, N. J., and Rupp, R. H. An anti-inflammatory cum immunomodulatory piperidinylbenzopyranone from Dysoxylum binectariferum: isolation, structure, and total synthesis. Tetrahedron, 44: 2081-2086, 1988.
13. Senderowicz, A. M., Headlee, D., Stinson, S. F., Lush, R. M., Kalil, N., Villalba, L., Hill, K., Steinberg, S. M., Figg, W. D., Tompkins, A., Arbuck, S. G., and Sausville, E. A. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J. Clin. Oncol., 16: 2986-2999, 1998. (Pubitemid 28417418)
14. Senderowicz, A. M. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials. Investig. New Drugs, 17: 313-320, 1999. (Pubitemid 30037961)
15. Kelland, L. R. Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status. Exp. Opin. Investig. Drugs, 9: 2903-2911, 2000.
16. Schwartz, G. K., Ilson, D., Saltz, L., O'Reilly, E., Tong, W., Maslak, P., Werner, J., Perkins, P., Stoltz, M., and Kelsen, D. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J. Clin. Oncol., 19: 1985-1992, 2001. (Pubitemid 32702543)
17. Stadler, W. M., Vogelzang, N. J., Amato, R., Sosman, J., Taber, D., Liebowitz, D., and Vokes, E. E. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago Phase II consortium study. J. Clin. Oncol., 18: 371-375, 2000. (Pubitemid 30056427)
18. Sedlacek, H. H. Mechanisms of action of flavopiridol. Crit. Rev. Oncol. Hematol., 38: 139-170, 2001. (Pubitemid 32328317)
19. Carlson, B., Lahusen, T., Singh, S., Loaiza-Perez, A., Worland, P. J., Pestell, R., Albanese, C., Sausville, E. A., and Senderowicz, A. M. Downregulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res., 59: 4634-4641, 1999. (Pubitemid 29428969)
20. ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol., 9: 469-479, 1999.
21. ARF gene deletion in high-grade adult and pediatric astrocytomas. Hum. Pathol., 31: 115-119, 2000.
22. Hunter, S. B., Abbott, K., Varma, V. A., Olson, J. J., Barnett, D. W., and James, C. D. Reliability of differential PCR for the detection of EGFR and MDM2 gene amplification in DNA extracted from FFPE glioma tissue. J. Neuropath. Exp. Neurol., 54: 57-64, 1995.
23. Wood, D. E., Thomas, A., Devi, L. A., Berman, Y., Beavis, R. C., Reed, J. C., and Newcomb, E. W. Bax cleavage is mediated by calpain during drug-induced apoptosis. Oncogene, 17: 1069-1078, 1998. (Pubitemid 28444591)
24. Schmid, I., Uittenbogaart, C. H., and Giorgi, J. V. Sensitive method for measuring apoptosis and cell surface phenotype in human thymocytes by flow cytometry. Cytometry, 15: 12-20, 1994.
25. Bible, K. C., and Kaufmann, S. H. Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res., 56: 4586-4861, 1996.
26. Arguello, F., Alexander, M., Sterry, J. A., Tudor, G., Smith, E. M., Kalavar, N. T., Greene, J. F., Koss, W., Morgan, C. D., Stinson, S. F., Siford, T. J., Alvord, W. G., Klabansky, R. L., and Sausville, E. A. Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood, 91: 2482-2490, 1998. (Pubitemid 28155524)
27. Rapoport, A. P., Simons-Evelyn, M., Chen, T., Sidell, R., Luhowskyj, S., Rosell, K., Obrig, T., Hicks, D., Hinkle, P. M., Nahm, M., Insel, R. A., and Abboud, C. N. Flavopiridol induces apoptosis and caspase-3 activation of a newly characterized Burkitt's lymphoma cell line containing mutant p53 genes. Blood Cells Mol. Dis., 27: 610-624, 2001. (Pubitemid 32757056)
28. Rosato, R. R., Almenara, J. A., Cartee, L., Betts, V., Chellappan, S. P., and Grant, S. The cyclin-dependent kinase inhibitor flavopiridol disrupts sodium butyrate-induced p21 WAF1/CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemia cells. Mol. Cancer Ther., 1: 253-266, 2002.
29. Gruss-Fischer, T., and Fabian, I. Protection by ascorbic acid from denaturation and release of cytochrome c, alteration of mitochondrial membrane potential and activation of multiple caspases induced by H2O2, in human leukemic cells. Biochem. Pharmacol., 63: 1325-1335, 2002. (Pubitemid 34312001)
30. Shapiro, G. I., Koestner, D. A., Matranga, C. B., and Rollins, B. J. Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines. Clin. Cancer Res., 5: 2925-2938, 1999. (Pubitemid 29493972)
31. Lu, K., Shih, C., and Teicher, B. A. Expression of pRB, cyclin/cyclin-dependent kinases and E2F1/DP-1 in human tumor lines in cell culture and in xenograft tissues and response to cell cycle agents. Cancer Chemother. Pharmacol., 46: 293-304, 2000.
32. Byrd, J. C., Shinn, C., Waselenko, J. K., Fuchs, E. J., Lehman, T. A., Nguyen, P. L., Flinn, I. W., Diehl, L. F., Sausville, E. A., and Grever, M. R. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood, 92: 3804-3816, 1998. (Pubitemid 28525207)
33. Motwani, M., Delohery, T. M., and Schwartz, G. K. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin. Cancer Res., 5: 1876-1883, 1999. (Pubitemid 29334472)
34. Susin, S. A., Lorenzo, H. K., Zamzami, N., Marzo, I., Snow, B. E., Brothers, G. M., Mangion, J., Jacotot, E., Constantini, P., Loeffler, M., Larochette, N., Goodlett, D. R., Aebersold, R., Siderovski, D. P., Penninger, J. M., and Kroemer, G. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature (Lond.), 397: 441-446, 1999.
35. Daugas, E., Susin, S. A., Zamzami, N., Ferri, K. F., Irinopoulou, T., Larochette, N., Prevost, M. C., Leber, B., Andrews, D., Penninger, J., and Kroemer, G. Mitochondrio-nuclear translocation of AIF in apoptosis and necrosis. FASEB J., 14: 729-739, 2000. (Pubitemid 30198571)
36. Cregan, S. P., Fortin, A., MacLaurin, J. G., Callaghan, S. M., Cecconi, F., Yu, S-W., Dawson, T. M., Dawson, V. L., Park, D. S., Kroemer, G., and Slack, R. S. Apoptosis-inducing factor is involved in the regulation of caspase-independent neuronal cell death. J. Cell Biol., 158: 507-517, 2002. (Pubitemid 34851709)
37. Wu, M., Xu, L-G., Li, X., Zhai, Z., and Shu, H-B. AMID, an apoptosis-inducing factor-homologous mitochondrion-associated protein, induces caspase-independent apoptosis. J. Biol. Chem., 277: 25617-25623, 2002. (Pubitemid 34951879)
38. Chao, S-H., and Price, D. H. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J. Biol. Chem., 276: 31793-31799, 2001.
39. Lam, L. T., Pickeral, O. K., Peng, A. C., Rosenwald, A., Hurt, E. M., Giltnane, J. M., Averett, L. M., Zhao, H., Davis, R. E., Sathyamoorthy, M., Wahl, L. M., Harris, E. D., Mikovits, J. A. Monks, A. P., Hollingshead, M. G., Sausville, E. A., and Staudt, L. M. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol., 2: 1-11, 2001.
40. Sausville, E. A. Complexities in the development of cyclin-dependent kinase inhibitor drugs. Trends Mol. Med., 8: 32-37, 2002.
41. Freedman, D. A., Wu, L., and Levine, A. J. Functions of the MDM2 oncoprotein. Cell. Mol. Life Sci., 55: 96-107, 1999. (Pubitemid 29077858)
42. Alarcon-Vargas, D., and Ronai, Z. p53-Mdm2: the affair that never ends. Carcinogenesis (Lond.), 23: 541-547, 2002. (Pubitemid 34498489)
43. Landers, J. E., Cassel, S. L., and George, D. L. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. Cancer Res., 57: 3562-3568, 1997. (Pubitemid 27355508)
44. Prasad, G., Wang, H., Agrawal, S., and Zhang, R. Antisense anti-MDM2 oligonucleotides as a novel approach to the treatment of glioblastoma multiforme. Anticancer Res., 22: 107-116, 2002. (Pubitemid 34475283)
45. Inoue, T., Geyer, R. K., Yu, Z. K., and Maki, C. G. Down-regulation of MDM2 stabilizes p53 by inhibiting p53 ubiquitination in response to specific alkylating agents. FEBS Lett., 490: 196-201, 2001. (Pubitemid 32171939)
46. Cordon-Cardo, C., Latres, E., Drobnjak, M., Oliva, M. R., Pollack, D., Woodruff, J. M., Marechal, V., Chen, J., Brennan, M. F., and Levine, A. J. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res., 54: 794-799, 1994. (Pubitemid 24068339)
47. Jones, S. N., Hancock, A. R., Vogel, H., Donehower, L. A., and Bradley, A. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc. Natl. Acad. Sci. USA, 95: 15608-15612, 1998. (Pubitemid 29018747)
48. Vogelstein, B., and Kinzler, K. W. p53 function and dysfunction. Cell, 70: 523-526, 1992.
49. Thomas, A., El Rouby, S., Reed, J. C., Krajewski, S., Silber, R., Potmesil, M., and Newcomb, E. W. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene, 12: 1055-1062, 1996. (Pubitemid 26104447)
50. Kroemer, G., and Reed, J. C. Mitochondrial control of cell death. Nat. Med., 6: 513-519, 2000. (Pubitemid 30305900)
51. Reed, J. C. Apoptosis-regulating proteins as targets for drug discovery. Trends Mol. Med., 7: 314-319, 2001. (Pubitemid 32606571)
52. Budihardjo, I., Oliver, H., Lutter, M., Luo, X., and Wang, X. Biochemical pathways of caspase activation during apoptosis. Annu. Rev. Cell Dev. Biol., 15: 269-290, 1999. (Pubitemid 32250377)
53. Schwartz, G. K., Farsi, K., Maslak, P., Kelsen, D. P., and Spriggs, D. Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells. Clin. Cancer Res., 3: 1467-1472, 1997. (Pubitemid 27431552)
54. Edelman, M. J., Mullins, B., Mack, P. C., Gumerlock, P. H., and Gandara, D. R. Synergistic interaction between flavopiridol (FLAVO) and Taxol (TAX) in a p53-null non-small cell lung carcinoma (NSCLC) cell line. Proc. Am. Assoc. Cancer Res., 39: 309-310, 1998.
55. Makhija, S., Jusain, A., Schwartz, G. K., and Spriggs, D. R. Cytotoxicity of flavopiridol in ovarian cancer cells, alone and in combination with CDDP. Proc. Am. Assoc. Cancer Res., 38: 320, 1997.